CEPI partners with Gennova Biopharmaceuticals for saRNA vaccine development against 'Disease X'

CEPI emphasizes the increasing risk of 'Disease X' outbreaks worldwide

CEPI provides $3.6 million to optimize self-amplifying mRNA (saRNA) platform technology

Vaccine candidate against rabies virus to be developed for preclinical studies.

Advances in RNA-vaccine tech critical for future pandemic responses.

SaRNA vaccines use genetic info to trigger host cells' self-amplification.

Gennova's unique CLNE delivery system for saRNA vaccines.

CEPI's funding aims for vaccine democratisation and equitable access.

Collaboration between CEPI and Gennova to enhance saRNA technology for global health.